H.C. Wainwright Maintains Calithera Biosciences Inc to Buy with Price Target $14

Brokerage firm H.C. Wainwright Maintains its rating on Calithera Biosciences Inc(CALA). As per the latest information, H.C. Wainwright Raises the price target to $14 per share from a prior target of $10. The shares have been rated Buy. The rating by the stock financial advisor at H.C. Wainwright was issued on Mar 28, 2017 in a research report to their Investors and Clients.

In a different note, On Jan 24, 2017, Citigroup said it Upgrades its rating on Calithera Biosciences Inc. The shares have been rated ‘Neutral’ by the firm.

Calithera Biosciences Inc (CALA) made into the market gainers list on Fridays trading session with the shares advancing 1.46% or 0.15 points. Due to strong positive momentum, the stock ended at $10.4, which is also near the day’s high of $10.7. The stock began the session at $10.2 and the volume stood at 10,61,850 shares. The 52-week high of the shares is $14.9 and the 52 week low is $2.2. The company has a current market capitalization of $285 M and it has 2,74,25,081 shares in outstanding.

Calithera Biosciences Inc(CALA) last announced its earnings results on Mar 16, 2017 for Fiscal Year 2016 and Q4.Earnings per share were $-0.45. Analysts had estimated an EPS of $-0.49.

Several Insider Transactions has been reported to the SEC. On Mar 15, 2017, Curtis Hecht (SVP, BUS. & CORP. DEVELOPMENT) sold 600 shares at $14.00 per share price.

Calithera Biosciences Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate CB-839 is an internally discovered inhibitor of glutaminase a critical enzyme in tumor metabolism. The Company is evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. The Company’s ongoing research efforts are focused on discovering additional product candidates against tumor metabolism and immunology targets.

Add Comment